3-nitrooxy-2,2-dimethylpropanoic acid chloride | 104963-55-5

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: 3-nitrooxy-2,2-dimethylpropanoic acid chloride
• 英文别名: 3-nitrooxypivaloyl chloride；2,2-dimethyl-3-(nitrooxy)propanoyl chloride；3-chloro-2,2-dimethyl-3-oxopropyl nitrate；(3-chloro-2,2-dimethyl-3-oxopropyl) nitrate
• CAS: 104963-55-5
• 化学式: C₅H₈ClNO₄
• 分子量: 181.576
• InChiKey: SRBNNNAAAKQFMB-UHFFFAOYSA-N

物化性质

• 沸点：
  216.9±23.0 °C(Predicted)
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-nitrooxy-2,2-dimethylpropanoic acid chloride 在 盐酸 、 三乙胺 作用下， 以 甲醇 为溶剂， 生成 [3-[(2-Hydroxy-3-naphthalen-1-yloxypropyl)-propan-2-ylamino]-2,2-dimethyl-3-oxopropyl] nitrate
  参考文献：
  名称：

  Synthesis and vasorelaxant properties of hybrid molecules out of NO-donors and the β-receptor blocking drug propranolol

  摘要：

  S-Nitroso-N-acetylpenicillamine (SNAP) and 3-nitrooxypivaloyl acid were combined in the form of the respective amides with propranolol, in order to obtain prodrugs (NO-propranololes) with beta-receptor blocking properties of the latter compound with nitric oxide releasing properties of the former compounds. A respective nitratoester could not be synthesized, because it immediately rearranges to the amide after deprotection of the amino group. In vitro tests on porcine pulmonary arteries showed that both types of hybrid molecules (6, 12) elicited vasorelaxation, but the nitratoamide was less potent by more than one order of magnitude. The vasorelaxant effect of SNAP was more pronounced than that of the SNAP-hybrid (12), on the other hand the nitratoamide 6 was more potent than 3-nitrooxypivaloyl acid. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.014
• 作为产物：
  描述：

  2,2-二甲基-3-(硝基氧基)丙酸 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以100%的产率得到3-nitrooxy-2,2-dimethylpropanoic acid chloride
  参考文献：
  名称：

  Nitric oxide enhancing diuretic compounds, compositions and methods of use

  摘要：

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。

  公开号：

  US20060189603A1

文献信息

• [EN] NITRIC OXIDE RELEASING COMPOUNDS FOR THE TREATMENT OF NEUROPHATIC PAIN<br/>[FR] COMPOSÉS LIBÉRANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DE DOULEURS NEUROPHATIQUES
  申请人：NICOX SA

  公开号：WO2011092065A1

  公开（公告）日：2011-08-04

  The present invention relates to nitric oxide releasing derivatives of serotonin norepinephrine reuptake inhibitors and their use for the treatment of pain, having the following general formula (I) or pharmaceutically acceptable salts thereof: wherein : A is selected from the formulas (1a) and (1b). The present invention also relates to pharmaceutical formulation comprising such derivatives, to a process for their preparation and to intermediates useful for their preparation.

  本发明涉及血清素去甲肾上腺素再摄取抑制剂的一氧化氮释放衍生物及其在治疗疼痛中的应用，具有以下一般式(I)或其药学上可接受的盐：其中：A选自式(1a)和(1b)。本发明还涉及包含这种衍生物的药物配方，以及用于它们的制备的过程和有用的中间体。
• [EN] DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS À DOUBLE FONCTION ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BIOFRONT THERAPEUTICS BEIJING CO LTD

  公开号：WO2022022669A1

  公开（公告）日：2022-02-03

  The present disclosure provides a compound configured to release nitric oxide (NO) and inhibit the activity of a phosphodiesterase (PDE) when administered to a subject. The compound may include L1 and L2. L1 may include a functional group that is part or all of a NO releasing agent. L2 may include a functional group that is part or all of a PDE inhibitor. The compound may further include a bond or a biradical that connects L1 and L2. The present disclosure further provides a method of treating or preventing a disease using the compound or a composition including the compound.

  本公开提供了一种化合物，当给予受试者时，该化合物被配置为释放一氧化氮(NO)并抑制磷酸二酯酶(PDE)的活性。该化合物可以包括L1和L2。L1可以包括作为一氧化氮释放剂的部分或全部的功能基团。L2可以包括作为磷酸二酯酶抑制剂的部分或全部的功能基团。该化合物还可以包括连接L1和L2的键或双自由基。本公开还提供了一种使用该化合物或包括该化合物的组成物治疗或预防疾病的方法。
• Thiazolidine derivatives
  申请人：Cedona Pharmaceuticals B.V.

  公开号：US05385922A1

  公开（公告）日：1995-01-31

  Thiazolidine derivatives containing at least one organic nitrate ester group have cardiovascular activity.

  含有至少一个有机硝酸酯基团的噻唑啉衍生物具有心血管活性。
• Aminopropanol derivatives, processes for the preparation thereof, the
  申请人：Boehringer Mannheim GmbH

  公开号：US04863949A1

  公开（公告）日：1989-09-05

  The present invention provides compounds of the general formula: ##STR1## wherein Ar is a substituted or unsubstituted aromatic or heteroaromatic radical, A is a straight-chained or branched alkylene chain containing up to 8 carbon atoms, a --CH.sub.2 -- group of which can be replaced by a cycloalkylene radical containing 3 to 7 carbon atoms, B is a straight-chained mono- or bicyclic, optionally branched, saturated or unsaturated alkylene chain containing up to 12 carbon atoms, a --CH.sub.2 -- group of which can be replaced by a cycloalkylene radical containing 3 to 7 carbon atoms and/or up to two --CH.sub.2 -- groups of which can be replaced by an oxygen or a sulphur atom or by an --S(.dbd.O) or --S(.dbd.O).sub.2 group, X is a valency bond, an oxygen atom or an --NR.sup.1 group, in which R.sup.1 is a hydrogen atom or a straight-chained or branched, saturated or unsaturated alkyl or nitroxyalkyl radical containing up to 6 carbon atoms or R.sup.1, together with the nitrogen atom of the --NR.sup.1 -- group and a --CH.sub.2 -- group of the chain B, can form a heteroaliphatic ring containing 4 to 6 carbon atoms and n is 1, 2 or 3; and the physiologically acceptable salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. Furthermore, the present invention is concerned with the use of these compounds for the treatment and/or prophylaxis of heart and circulatory diseases.

  本发明提供了一般式为：##STR1##的化合物，其中Ar是取代或未取代的芳香或杂环芳香基团，A是含有最多8个碳原子的直链或支链烷基链，其中一个--CH.sub.2--基团可被含有3至7个碳原子的环烷基团替代，B是含有最多12个碳原子的直链单环或双环、可选地支链、饱和或不饱和的烷基链，其中一个--CH.sub.2--基团可被含有3至7个碳原子的环烷基团替代和/或最多两个--CH.sub.2--基团可被氧原子或硫原子或--S(.dbd.O)或--S(.dbd.O).sub.2基团替代，X是一个价键，一个氧原子或一个--NR.sup.1基团，其中R.sup.1是一个氢原子或一个含有最多6个碳原子的直链或支链、饱和或不饱和的烷基或亚硝基烷基基团，或R.sup.1与--NR.sup.1--基团的氮原子和链B中的一个--CH.sub.2--基团可形成含有4至6个碳原子的杂环脂肪环，n为1、2或3；以及其生理上可接受的盐。本发明还提供了制备这些化合物的方法和含有它们的制药组合物。此外，本发明涉及这些化合物用于治疗和/或预防心脏和循环疾病的用途。
• NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：GARVEY David S.

  公开号：US20080255101A1

  公开（公告）日：2008-10-16

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  这项发明描述了新颖的组合物和试剂盒，包括至少一种增强一氧化氮利尿化合物或其药学上可接受的盐，并且可选地，还包括至少一种增强一氧化氮化合物和/或至少一种治疗剂。该发明还提供了以下方法：(a)治疗由过度水和/或电解质潴留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗先兆子痫；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)治疗高脂血症。增强一氧化氮利尿化合物包括至少一个增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点连接到利尿化合物上，通过无法水解的键或基团连接。